Pin1-Targeted Therapy for Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease with limited therapeutic options.
• The Toll-like receptor 7 (TLR-7)/TLR-9/interleukin-1 receptor-associated kinase 1 (IRAK-1)/interferon regulatory factor 7 (IRF-7) pathway is implicated in SLE pathogenesis.
• The role of prolyl isomerase Pin1 in SLE is currently unknown.

Purpose of the Study:

• To investigate Pin1 activation in SLE.
• To determine the role of Pin1 in SLE development and potential therapeutic strategies targeting Pin1.

Main Methods:

• Assessed Pin1 and TLR signaling activation in immune cells from healthy controls and SLE patients.
• Utilized Pin1 short hairpin RNA (shRNA), genetic knockout, and the small-molecule inhibitor all-trans-retinoic acid (ATRA) in immune cells and lupus-prone mouse models.

Main Results:

• Abnormal Pin1 and downstream IRAK-1/IRF-7 activation was observed in SLE patients.
• Pin1 inhibition blocked TLR-7-induced IRAK-1/IRF-7 activation in SLE patient immune cells.
• Pin1 inhibition in lupus-prone mice attenuated autoimmune manifestations and prolonged survival.

Conclusions:

• Pin1 plays a critical role in SLE development.
• Targeting Pin1 represents a promising therapeutic strategy for SLE treatment.